article thumbnail

Scientists discover a cause of lupus and a possible way to reverse it

Science Daily: Pharmacology News

Scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus (known as lupus) and show that reversing this defect may potentially reverse the disease.

article thumbnail

Using next-gen CRISPR tool, scientists create unprecedented molecular map of human immune response

Science Daily: Pharmacology News

In a study of historic scale, scientists have created an intricate map of how the immune system functions, examining the detailed molecular structures governing human T cells using the next-generation CRISPR tool known as base editing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Immuno-oncology innovations redefining cancer treatment in 2024

Drug Target Review

Individualised cancer vaccines are tailored to each patient’s tumour, helping the immune system mount cancer-specific immune responses that can boost checkpoint inhibitor efficacy. Espen integrates clinical and research expertise as Director of Medical Affairs.

Treatment 122
article thumbnail

Gene editing precisely repairs immune cells

SCIENMAG: Medicine & Health

Some hereditary genetic defects cause an exaggerated immune response that can be fatal. Using the CRISPR-Cas9 gene-editing tool, such defects can be corrected, thus normalizing the immune response, as researchers led by Klaus Rajewsky from the Max Delbrück Center now report in “Science Immunology.”

article thumbnail

Study reveals how some bacterial infections become chronic

Broad Institute

By examining the genomes of bacteria collected from hundreds of people with persistent Salmonella infections, they discovered genetic mutations that both reduce the bacteria’s “virulence,” or ability to infect, and dampen the host’s immune responses, creating a kind of molecular camouflage that shields the bacteria from the immune system’s gaze.

article thumbnail

Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses

The Pharma Data

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

article thumbnail

New mRNA vaccine created to prevent and treat C. difficile

Science Daily: Pharmacology News

difficile first-time infections and relapsing infections by inducing a robust immune response, promote clearance of existing C. diff bacteria from the gut, and even overcome deficits in host immunity to protect animals after infection, according to researchers. In animal models, this first mRNA-LNP C.

Vaccine 118